Skip Navigation


Annals of Oncology Advance Access originally published online on December 3, 2007
Annals of Oncology 2008 19(3):570-576; doi:10.1093/annonc/mdm543
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/3/570    most recent
mdm543v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pettengell, R.
Right arrow Articles by Wild, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pettengell, R.
Right arrow Articles by Wild, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

quality of life

The impact of follicular lymphoma on health-related quality of life

R. Pettengell1,*, C. Donatti2, P. Hoskin3, C. Poynton4, P. J. Kettle5, B. Hancock6, S. Johnson7, M. J. S. Dyer8, S. Rule9, M. Walker10 and D. Wild2

1 Haematology and Oncology, St George's Hospital, London
2 Oxford Outcomes Ltd, Oxford
3 Mount Vernon Cancer Centre, Northwood, Middlesex
4 Department of Haematology, University Hospital of Wales, Heath Park, Cardiff, Wales
5 Belfast City Hospital
6 Western Park Hospital, Sheffield Hospital, Sheffield
7 Department of Haematology, Taunton and Somerset Hospital, Musgrove Park, Taunton
8 Haemato-Oncology, MRC Toxicology Unit / Leicester University, Leicester
9 Derriford Hospital, Plymouth
10 Healthcare Management, Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK

* Correspondence to: Dr R. Pettengell, Department of Haematology, St George's University of London, Cranmer Terrace, London SW170RE, UK. Tel: +44-20-87255454; Fax: +44-20-87252859; E-mail: rpetteng{at}sghms.ac.uk

Background: The purpose of this study was to determine whether there was a relationship between disease activity and health functioning, as measured by a range of patient-reported outcome (PRO) measures in patients with follicular lymphoma (FL).

Patients and methods: A total of 222 patients with FL were recruited from eight sites across the UK and they completed a number of PRO measures. The participants were analyzed across five disease states: ‘active disease—newly diagnosed’, ‘active disease—relapsed’, ‘partial response’, ‘complete response’ and ‘disease free’. The relationship between these disease states and their level of health functioning was assessed as well as the relationship between being ‘on’ or ‘off’ chemotherapy and disease state.

Results: In terms of health-related quality of life (HRQoL), participants in the relapsed category had the lowest mean physical well-being, emotional well-being, functional well-being and social well-being score. In a regression analysis, the ‘active disease–relapsed’ group acted as a significant predictor for each PRO variable. In addition, the remission group acted as a significant predictor of high anxiety scores as measured by the Hospital Anxiety and Depression Scale.

Conclusion: The results of this study demonstrate that various aspects of patient-reported health outcomes differ according to disease state in patients with FL. For those patients who have relapsed, they are more likely to experience worse HRQoL and other patient-reported health outcomes than patients newly diagnosed, in partial or complete remission or when completely disease free.

Key words: FACT-LYM, follicular lymphoma, HRQoL, PRO, relapse, remission

Received for publication May 3, 2007. Revision received October 22, 2007. Accepted for publication October 25, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.